Intrauterine therapy for macrocystic congenital cystic adenomatoid malformation of the lung
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveTo report on our experiences with thoracoamniotic shunting and/or the injection of a sclerosing agent (OK-432) to treat fetuses diagnosed with macrocystic congenital cystic adenomatoid malformation (CCAM) of the lung. MethodsA retrospective study was undertaken in six fetuses with macrocystic CCAM at our institute that had been confirmed by postnatal surgery between August 1999 and January 2012. ResultsSix fetuses that had been diagnosed with macrocystic CCAM were analyzed. The median gestational age at diagnosis was 23.5 weeks (range, 19.5–31.0 weeks), and at the time of primary treatment was 24.0 weeks (range, 20.5–31.0 weeks). The mean size of the largest cyst at the initial assessment was 42.5±15 mm. Four fetuses were associated with mediastinal shifting, and one also showed fetal hydrops. All fetuses underwent a shunting procedure within the cysts, one case among them was also treated with OK-432. After the completion of all procedures, the mean size of the largest cyst was all decreased (14.2±12 mm). The median gestational age at delivery was 38.0 weeks (range, 32.4–40.3 weeks). All of the newborns underwent the surgical resection at a median age of 6 days (range, 1–136 days) and are currently doing well without any complications. ConclusionWe suggest that intrauterine decompression therapy to manage fetal macrocystic CCAM is recommendable treatment for good perinatal outcome.
Abstract
ObjectiveTo report on our experiences with thoracoamniotic shunting and/or the injection of a sclerosing agent (OK-432) to treat fetuses diagnosed with macrocystic congenital cystic adenomatoid malformation (CCAM) of the lung. MethodsA retrospective study was undertaken in six fetuses with macrocystic CCAM at our institute that had been confirmed by postnatal surgery between August 1999 and January 2012. ResultsSix fetuses that had been diagnosed with macrocystic CCAM were analyzed. The median gestational age at diagnosis was 23.5 weeks (range, 19.5–31.0 weeks), and at the time of primary treatment was 24.0 weeks (range, 20.5–31.0 weeks). The mean size of the largest cyst at the initial assessment was 42.5±15 mm. Four fetuses were associated with mediastinal shifting, and one also showed fetal hydrops. All fetuses underwent a shunting procedure within the cysts, one case among them was also treated with OK-432. After the completion of all procedures, the mean size of the largest cyst was all decreased (14.2±12 mm). The median gestational age at delivery was 38.0 weeks (range, 32.4–40.3 weeks). All of the newborns underwent the surgical resection at a median age of 6 days (range, 1–136 days) and are currently doing well without any complications. ConclusionWe suggest that intrauterine decompression therapy to manage fetal macrocystic CCAM is recommendable treatment for good perinatal outcome.
참고문헌 (24)
- Bunduki V, "Prognostic factors associated with congenital cystic adenomatoid malformation of the lung", Prenat Diagn, 20, pp.459~464 (2000)
- Wilson RD, "Cystic adenomatoid malformation of the lung: review of genetics, prenatal diagnosis, and in utero treatment", Am J Med Genet A, 140, pp.151~155 (2006)
- Mahle WT, "Echocardiographic evaluation of the fetus with congenital cystic adenomatoid malformation", Ultrasound Obstet Gynecol, 16, pp.620~624 (2000)
- Davenport M, "Current outcome of antenally diagnosed cystic lung disease", J Pediatr Surg, 39, pp.549~556 (2004)
- Adzick NS, "Fetal lung lesions: management and outcome", Am J Obstet Gynecol, 179, pp.884~889 (1998)
- Crombleholme TM, "Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung", J Pediatr Surg, 37, pp.331~338 (2002)
- Adzick NS, "Fetal surgery for cystic adenomatoid malformation of the lung", J Pediatr Surg, 28, pp.806~812 (1993)
- Nugent CE, "Prenatal treatment of type I congenital cystic adenomatoid malformation by intrauterine fetal thoracentesis", J Clin Ultrasound, 17, pp.675~677 (1989)
- Schrey S, "Fetal thoracoamniotic shunting for large macrocystic congenital cystic adenomatoid malformations of the lung", Ultrasound Obstet Gynecol, 39, pp.515~520 (2012)
- Ierullo AM, "Neonatal outcome of antenatally diagnosed congenital cystic adenomatoid malformations", Ultrasound Obstet Gynecol, 26, pp.150~153 (2005)
- Clark SL, "Successful fetal therapy for cystic adenomatoid malformation associated with second-trimester hydrops", Am J Obstet Gynecol, 157, pp.294~295 (1987)
- Dommergues M, "Congenital adenomatoid malformation of the lung: when is active fetal therapy indicated?", Am J Obstet Gynecol, 177, pp.953~958 (1997)
- Stocker JT, "Congenital cystic adenomatoid malformation of the lung. Classification and morphologic spectrum", Hum Pathol, 8, pp.155~171 (1977)
- Evrard V, "Congenital parenchymatous malformations of the lung", World J Surg, 23, pp.1123~1132 (1999)
- Gilbert-Barness E, "Embryo and fetal pathology: color atlas with ultrasound correlation" (2004), Cambridge University Press
- Adzick NS, "Management of congenital lung lesions", Semin Pediatr Surg, 12, pp.10~16 (2003)
- Chung JY, "The fetal therapy of congenital cystic adenomatoid malformation of the lung in-utero: two cases of thoracoamniotic shunting using a basket-shaped catheter", Korean J Obstet Gynecol, 43, pp.1894~1899 (2000)
- Chen M, "Antenatal treatment of chylothorax and cystic hygroma with OK-432 in nonimmune hydrops fetalis", Fetal Diagn Ther, 20, pp.309~315 (2005)
- Ogita K, "Outcome of fetal cystic hygroma and experience of intrauterine treatment", Fetal Diagn Ther, 16, pp.105~110 (2001)
- Bermudez C, "Percutaneous ultrasound-guided sclerotherapy for complicated fetal intralobar bronchopulmonary sequestration", Ultrasound Obstet Gynecol, 29, pp.586~589 (2007)
- Bermudez C, "Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung", Fetal Diagn Ther, 24, pp.237~240 (2008)
- Lee FL, "Treatment of congenital pulmonary airway malformation induced hydrops fetalis via percutaneous sclerotherapy", Fetal Diagn Ther, 31, pp.264~268 (2012)
- Luzzatto C, "Sclerosing treatment of lymphangiomas with OK-432", Arch Dis Child, 82, pp.316~318 (2000)
- Kurokawa T, "Clinical experiences with the streptococcal anticancer preparation, OK-432 (NSCB116209)", Cancer Chemother Rep, 56, pp.211~220 (1972)